Experimental chemotherapy uses stealth tactic to activate inside cancer cells
Chemotherapy faces a fundamental problem: The same drugs powerful enough to kill cancer cells can also damage healthy tissue. UC Irvine researchers are trying to change that equation by putting a safety lock on a highly potent cancer drug—a lock designed to be removed once the drug enters cancer cells with high levels of a specific protein-destroying activity.
An experimental chemotherapy approach has been developed by researchers at UC Irvine, which uses a unique strategy to selectively activate chemotherapy drugs inside cancer cells. The team designed a prodrug that contains a potent anticancer agent called monomethyl auristatin E (MMAE) attached to a peptide recognized by the immunoproteasome, a specialized form of the cell's protein-recycling machinery.
In the presence of elevated immunoproteasome activity found in some cancer cells, the peptide is cleaved, releasing the toxic MMAE drug. This approach effectively locks away the chemotherapy agent until it reaches cancer cells with high immunoproteasome activity, allowing for safer and more targeted treatment. Unlike traditional targeted therapies that require identifying specific surface markers on cancer cells, this method exploits the unique biological differences inside cancer cells.
The researchers tested the prodrug in small cell lung cancer cells in the lab and observed significant tumor reduction without toxic effects in preclinical models. While early results show promise, further research is needed to determine its clinical effectiveness in humans.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
